• Artiva Biotherapeutics disclosed initial clinical results for AlloNK with rituximab across several autoimmune diseases, with additional data slated for presentation at EULAR 2026.
• Early findings in hard-to-treat rheumatoid arthritis showed many patients achieved meaningful symptom relief that held through follow-up, with no need to add new immune-suppressing medicines.
• Safety profile supported outpatient use, with no severe immune-related toxicities reported and no treatment stoppages tied to adverse events.
• FDA alignment cleared path for a single Phase 3 registrational trial in refractory rheumatoid arthritis starting in H2 2026, testing AlloNK with rituximab versus rituximab alone in about 150 patients.
• Company targets primary readout in H2 2028, with a potential biologics license application submission in 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080630PRIMZONEFULLFEED9716143) on May 08, 2026, and is solely responsible for the information contained therein.